Distinguished in IgG4-Related Disease

Masatoshi Kudo

Osaka, JP 
Distinguished in IgG4-Related Disease
Osaka, JP 
OverviewLocationsClinical Research

Overview

Masatoshi Kudo practices in Osaka, Japan. Mr. Kudo is rated as a Distinguished expert by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Liver Cancer, Jaundice, Hepatitis, Endoscopy, and Gastrostomy.

His clinical research consists of co-authoring 1131 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of IgG4-Related Disease.

Gender
Male

Locations

Osaka, Japan
Other Locations
Japan
Sakai, 5900197, Japan
Sayama, 5898511, Japan
Higashi-osaka, Japan
Kobe, Japan
Sayama, Japan
Tokyo, Japan
Ono, 5898511, Japan
Kitano, 5898511, Japan
Sakai, Japan
Shizuoka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Enrollment Status: Completed
Publish Date: December 05, 2022
Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)
Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)
Enrollment Status: Unknown
Publish Date: October 31, 2017
Intervention Type: Procedure, Drug
Study Drug: Transcatheter Arterial Chemoembolization with Sorafenib
Study Phase: Phase 2
View 4 Less Clinical Trials

1131 Total Publications

Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab.
Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab.
Journal: Internal medicine (Tokyo, Japan)
Published: November 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kudo's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 32 Advanced Conditions
View All 98 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile